NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE I DIABETES

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是开发未来的研究，帮助研究人员更多地了解1型糖尿病的预防和糖尿病是如何发生的。 1型糖尿病患者的亲属患这种疾病的风险是没有家族史的人的10到15倍。正因为如此，我们有兴趣观察1型糖尿病患者的近亲。 这项研究分为三个阶段：筛选阶段1、基线风险评估阶段2和后续风险评估阶段3。 第一阶段-研究的筛查阶段包括检测血液中的糖尿病相关自身抗体。自身抗体是由身体--S免疫系统--制造的蛋白质。如果这些蛋白质存在，可能意味着胰腺中产生胰岛素的细胞受损。在1型糖尿病发生前几年，血液中就可以发现自身抗体。可以看到几种不同的自身抗体。 第二阶段-进行更多的测试，以发现或评估1型糖尿病的风险。 第三阶段-是为那些测试结果显示他们比其他人患1型糖尿病的风险更高的受试者准备的。它包括几个正在进行的风险评估测试，以确定这些受试者是否有资格参加任何糖尿病预防试验

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to develop future studies that will help researchers to learn more about the prevention of type 1 diabetes and how diabetes occurs. Relatives of people with type 1 diabetes have a 10 to 15 times greater risk for the disease than people with no family history. Because of this, we are interested in looking at close blood relatives of people with type 1 diabetes. The study is divided into three phases: Screening Phase 1, Baseline Risk Assessment Phase 2, and Follow-Up Risk Assessments Phase 3. Phase I - The screening phase of the study includes testing for diabetes related autoantibodies in the blood. Autoantibodies are proteins that are made by the body?s immune system. If these proteins are present, it could mean that cells in the pancreas that produce insulin are damaged. Autoantibodies can be found in the blood years before type 1 diabetes occurs. Several different kinds of autoantibodies can be seen. Phase II - More testing done to find out or estimate the risk for type 1 diabetes. Phase III - Is for those subjects whose test results showed that they are at a higher risk of developing type 1 diabetes than others. It involves several ongoing risk assessment tests to see if these subjects might be eligible to participate in any diabetes prevention trials